Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799063 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL19704119 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL19704283 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL5764149 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2RECQLGPR119DDB1 | |
| SCHEMBL5766899 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2RECQLGPR119DDB1 | |
| SCHEMBL5764143 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2RECQLGPR119DDB1 | |
| SCHEMBL1344048 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2RECQLGPR119DDB1 | |
| SCHEMBL29548956 | 0.79 | HPGD (0.48) | USP2SMN1; SMN2RECQLGPR119DDB1 | |
| SCHEMBL19736069 | 0.78 | USP2 (0.43) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL29715575 | 0.77 | USP2 (0.42) | USP2SMN1; SMN2RECQLGPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-114981268-B | Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and application thereof in medicine | 北京诺诚健华医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-112625028-B | Compounds and compositions for inhibiting SHP2 activity | 诺华股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3753941-B1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-04-09 | — | — | US | disclosed |
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | NAVIRE PHARMA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| CN-112351780-B | Substituted heterocyclic inhibitors of PTPN11 | 纳维尔制药有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| WO-2015107495-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| EP-1603901-B1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-7393858-B2 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-07-01 | — | — | US | disclosed |
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-08-03 | — | — | US | disclosed |
| EP-1603901-A1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078750-A1 | TETRAHYDROPYRAN COMPOUNDS AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172999-A1 | Tetrahydropyran compounds as tachykinin antagonists | NPSR1, NPY1R, OPRL1 | USP2 4186/4885SMN1; SMN2 4072/4885RECQL 1073/4885 |
| US-11952386-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885RECQL 786/4885 |
| US-11932643-B2 | Substituted heterocyclic inhibitors of PTPN11 | PTPN11, PTPRJ, PTPRCAP | USP2 1009/4885SMN1; SMN2 4080/4885RECQL 1972/4885 |
| US-20170015680-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885RECQL 786/4885 |
| US-12209098-B2 | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN7 | USP2 1924/4885SMN1; SMN2 2598/4885RECQL 786/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | USP2 1045/4885SMN1; SMN2 4183/4885RECQL 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.